One Zyme isn't a single model with a search box bolted on. It routes every question to the model best suited to the job, and because we do only biopharma, each one runs on context no general-purpose system can match.
From the models at the bottom to the reports and agents at the top, every layer is engineered specifically for biopharma. Explore each one.
No single model is best at everything. One Zyme runs a portfolio of specialized and frontier models, each doing the part of the job it's best at, coordinated into a single pipeline behind one interface.
Parses intent, entities, and scope out of a natural-language question.
Biomedical embeddings pull the exact trials, patents, filings, and literature that matter.
Specialized and frontier models analyze the evidence in parallel.
Models check one another's work and reconcile every finding against the sources.
Findings assembled into a decision-ready, fully source-cited answer.
A general-purpose model sees your question as text. One Zyme sees it through layers of biomedical structure, the ontologies, graphs, and schemas that let it reason like a domain expert.
One Zyme continuously assembles global and China-native sources, clinical, scientific, regulatory, financial, and corporate, into one structured, source-cited intelligence layer your team can query directly.
Global & China trial registries, protocols, endpoints, sponsors, and investigators.
Peer-reviewed literature, preprints, conference abstracts, and posters.
FDA, EMA, NMPA & CDE filings, approvals, designations, and priority reviews.
SEC disclosures, fundings, M&A, licensing, pipelines, and company structure.
The same company appears a dozen ways across sources. One Zyme links them, so a trial in Suzhou, a patent family, and an SEC disclosure all point to the same asset.
The models do the reasoning; the evidence layer keeps them honest. Each claim carries a clickable, dated citation, built for the rigor biopharma decisions demand.
Answers are assembled from retrieved evidence, not produced from a model's memory and hoped to be right.
Each statement links to the exact trial, filing, patent, or paper it came from, with the date attached.
Sources are continuously refreshed and timestamped, so you can see exactly how current the evidence is.
Get a strategic briefing tailored to your therapeutic areas, competitors, and watchlists, and watch the platform reason over real biopharma evidence.
